FXI concentrate use and risk of thrombosis

Haemophilia

Volumn 20, Issue 4, 2014, Pages

  Bolton Maggs, P ^a   Goudemand, J ^b   Hermans, C ^c   Makris, M ^d   de Moerloose, P ^e  

^a Manchester Blood Centre   (United Kingdom)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR CONCENTRATE; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

BLOOD CLOTTING FACTOR 11 DEFICIENCY; CEREBROVASCULAR ACCIDENT; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; FIBRINOLYSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LETTER; LOW DRUG DOSE; LUNG EMBOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOGENICITY; TRANSIENT ISCHEMIC ATTACK; ADULT; AGED; CHEMICALLY INDUCED; FACTOR XI DEFICIENCY; MIDDLE AGED; RISK; THROMBOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FACTOR XI; FACTOR XI DEFICIENCY; HUMANS; MIDDLE AGED; RISK; THROMBOSIS;

EID: 84904708805     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12457     Document Type: Letter

References (10)

1. Bolton Maggs P. Factor XI deficiency-resolving the enigma? Hematology Am Soc Hematol Edu Program 2009: 97-105.
2. Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A; Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/FIX Scientific Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012, 10: 1938-43.
3. Rugeri L, Quelin F, Chatard B, De Mazancourt P, Negrier C, Dargaud Y. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia 2010; 16: 771-7.
4. Gueguen P, Galinat H, Blouch MT et al. Biological determinants of bleeding in patients with heterozygous factor XI deficiency. Br J Haematol 2012; 156: 245-51.
5. Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-9.
6. Mannucci PM, Bauer KA, Santagostino E et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 1314-9.
7. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
8. Livnat T, Tamarin I, Mor Y et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102: 487-92.
9. O'Connell NM, Riddell AF, Pascoe G, Perry DJ, Lee CA. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia 2008; 14: 775-81.
10. Roemisch JR. Identification of activated FXI as the major biochemical root cause in IVIG batches associated with thromboembolic events. Available at http://webmedcentralcom/article_view/2002. Accessed December 20, 2013.